Xarelto Defendants: Third Time Lucky
Xarelto Defendants: Third Time Lucky
Introduction
The third straight win for Xarelto defendants in the Xarelto MDL No. 2592 bellwether trial, boosts the defendant's stand regarding the safety and efficacy of Xarelto. Bayer released a statement saying, ''that its FDA-approved label contains accurate, science-based information on the benefits and risks of this life-saving medicine.” This decision came in by the Mississippi federal jury in favor of the defendants: J&J's Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. The plaintiff alleged that the Prothrombin Time (PT) test which is used to assess a patient's risks for bleeding, was not informed and instructed to the doctors by the manufacturers. This was opposed by the defendant's say that the PT test was not scientifically reliable.
Comments
Latest News
Supreme Court Upholds Flavored Vape Ban
Categories: E-Cigarette: JUUL
The U.S. Supreme Court has unanimously upheld a decision by the Food and Drug Administration (FDA) to block the sale and marketing of certain flavored e-cigarette products.
The ruling supports the FDA’s authority to regulate tobacco…
Judge Rejects JnJ's $10B Talc Lawsuit Settlement
Categories: Talcum
Johnson & Johnson's shares fell more than 5% after a U.S. bankruptcy judge rejected its $10 billion settlement proposal aimed at resolving over 60,000 lawsuits.
These lawsuits allege that the company’s…
Tepezza Hearing Loss MDL: Bellwether Trials Set for 2026
Categories: Tepezza
A U.S. District Judge overseeing Tepezza hearing damage lawsuits nationwide has scheduled four bellwether trials for 2026. These trials are intended to help both parties assess how juries may respond to the evidence and testimonies that could be…